AstraZeneca pluck chief exec from rival Roche
AstraZeneca yesterday poached its new chief executive from Swiss rival Roche in a bid to kick-start the UK drugs giant, which will see many of its top-selling drugs come off patent in the next two years.
The company has also suffered a series of multi-million pound clinical trial failures.
Pascal Soriot, 53, who practised as a vet before moving into the pharmaceutical industry, will join AstraZeneca at the start of October.
He headed the cancer drug group Genentech before its $100m (£63m) takeover by Roche in 2009, where he became head of pharmaceuticals.
Frenchman Mr Soriot replaces David Brennan, who became one of the most high-profile casualties of the shareholder spring. Mr Brennan resigned in April, hours before the firm's annual meeting.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies